RELATED PRODUCTS NOT AVAILABLE
May help reduce cost and delays in treatment
BD Nexiva {*} has been shown to reduce costs and reduce treatment delays in clinical studies.**,1,3
Dwells longer
In a randomized study comparing the BD Nexiva {*} to an open catheter system*, among peripheral IV catheters in place for over 24 hours, the median dwell time for BD Nexiva™ {*} was up to 144 hours versus 96 hours for the open system.*,1
Preserves sites
BD Nexiva {*} is an all-in-one PIVC shown to preserve sites for longer.†,1,3
Lessens blood exposure
By choosing the BD Nexiva {*}, you can reduce the risk of complications and blood exposure as well as preserve sites.**,1,3
Pre-attached extension set
BD Nexiva {*} with integrated extension tubing and stabilization platform reduces the risk of dislodgement and related complications.‡,1,3
Reduces accidental dislodgement
The BD Nexiva {*} with the built-in stabilization platform reduces dislodgement by 84%.‡,3
BD Nexiva {*} with an integrated extension tubing and stabilization platform is designed to reduce manipulation and movement at the site and has been shown to reduce dislodgement and phlebitis.‡,1,3
First attempt insertion
BD Instaflash™ Needle Technology incorporates a notched needle, which is designed to improve first-stick success and reduce painful hit-and-miss insertions.4,5
BD Instaflash™ Needle Technology
Incorporates a notched needle designed to provide immediate visual confirmation of vessel entry.5,6
Lowers chance of mechanical phlebitis
The BD Nexiva {*} demonstrated a 29% reduction in phlebitis rates when compared to an open system.*,1
Proprietary BD Vialon™ Catheter Material softens, enabling longer dwell time and reducing the chance of phlebitis up to 69%.§,7-9
BD Nexiva™: Traditional vs closed IV catheter insertion
Catheter stabilization is recognized as an intervention to decrease the risk for phlebitis, catheter migration and dislodgement and may be advantageous in preventing catheter-related bloodstream infections (CRBSIs).3
Recommend limiting the use of add-on devices to reduce the potential for contamination, additional manipulation, and disconnection.5
98% reduced blood exposure during insertion due to the BD Nexiva IV catheter preassembled system.2*
Clinically demonstrated to reduce accidental dislodgement,2‡ meeting Infusion Nursing Society standards4 and CDC guidelines5 for catheter stabilization.
In a clinical study, results demonstrated a significant reduction in the rate of phlebitis (grade 2 or higher), PIVC-related complications, and infiltration in the closed system versus the open system group.1
BD offers training resources to help improve your clinical practices as part of our goal of advancing the world of health.
BD supports the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.
*With an PTFE catheter.
**Compared to an open system.
†Up to 144 hours compared to 96 hours with an open system with a PTFE catheter.
‡BD NexivaTM Catheter System with 3MTM TegadermTM IV Securement Dressing compared to B. Braun Introcan Safety® catheter with Statlock® IV Ultra stabilization device and non-bordered dressing.
§Compared to an FEP catheter.
BD-3595 (10/23)